Grade 10: Salary in range £56,587 - £65,574 per annum: University of Oxford : We are seeking a Head of Translational and Operational Bioinformatics to join our team at The University of Oxford. Oxford

Notice NOT-OD-22-115 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-114 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-166 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for support of mature structural biology resources at synchrotron facilities. Mature refers to the techniques made available at the resource beamlines: they must be well-established, requiring no significant novel technology development in order to provide utility to the communities they serve or to maintain them as state-of-the-art beamlines. This funding opportunity is limited to resources whose operations recently have been or currently are being supported by NIGMS funding. The intent is to provide access to X-ray beamlines for structural biology research. It is expected that the facility will be maintained or upgraded to current best practices, make its capability and availability known to the biomedical research community through outreach activities, and provide user training and support

Funding Opportunity PAR-22-163 from the NIH Guide for Grants and Contracts. The National Institute of General Medical Sciences (NIGMS) invites applications for renewal of eligible Centers of Biomedical Research Excellence (COBRE) grants. The objective of the COBRE initiative is to strengthen an institution's biomedical research infrastructure through the establishment of a thematic, multi-disciplinary center and to enhance the ability of investigators to compete independently for NIH individual research grants or other external peer-reviewed support. COBRE awards are supported through the Institutional Development Award (IDeA) Program, which aims to foster health-related research by increasing the competitiveness of investigators at institutions located in states with historically low aggregate success rates for grant awards from the NIH. The goal of this FOA is to support existing COBRE Phase 1 Centers by further strengthening the research infrastructure and to continue the development and support of a critical mass of investigators with the expertise in the Center's scientific interest areas.

Funding Opportunity RFA-AG-23-028 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to define and characterize neuronal and glial cell populations that are vulnerable to Alzheimer's disease (AD) and AD-related dementias (ADRD) proteinopathies.

Notice NOT-MD-22-016 from the NIH Guide for Grants and Contracts

Notice NOT-HD-22-003 from the NIH Guide for Grants and Contracts

Represent Data Management in governance bodies, product teams and cross-functional groups; lead internal working groups.
From Seagen - Tue, 19 Apr 2022 00:29:40 GMT - View all Bothell, WA jobs

Funding Opportunity PAR-22-142 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may include Phase 1 and 2 studies of drugs and biologics, feasibility studies of devices, and early studies of surgical, behavioral or rehabilitation therapies. All exploratory trials must contribute to the justification for and provide some of the data required to inform a future trial to establish efficacy (such as a Phase 3, Phase 4 or Pivotal trial). This FOA uses the UG3/UH3 mechanism. Only projects that provide satisfactory progress in the UG3 phase may move to the UH3 phase, as outlined below. For a drug, biologic or device that has not completed a Phase 1/Early Feasibility trial: The UG3 mechanism will be used to plan and execute the Phase I trial(s). If Phase 1 trials are successful, the UG3 will also include the planning phase of a Phase 2 trial. The UH3 mechanism will then support the execution of the Phase 2 clinical trial. Transition to the UH3 will depend on successfully reaching agreed upon milestones. For a drug, biologic or device that has successfully completed the Phase 1/Early Feasibility trial(s), do not use this FOA. Instead use the Companion FOA XXX. For genetic studies, do not use this FOA. Instead, use FOA XXX.

Notice NOT-CA-22-081 from the NIH Guide for Grants and Contracts

Notice NOT-DA-22-055 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-105 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-108 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-080 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-22-024 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement (FOA) for the Common Fund Program "Illuminating the Druggable Genome" (IDG; https://commonfund.nih.gov/idg/index) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDGs Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches.Awards will support the generation of additional data and tools around understudied protein(s) identified by the IDG Program to elucidate the function of these proteins in the context of human disease. Data collected and tools generated by these projects will enhance the overall goals of the IDG Program by demonstrating the quality and utility of IDG-generated data and reagents to the scientific community, increasing awareness of the IDG Program through use of IDG-generated resources, and/or extending the characterization of IDG-eligible proteins.

Preferred in bioinformatics, data science, computational biology, or related discipline. 25% Implements appropriate data science techniques under the guidance…
From University of Wisconsin–Madison - Thu, 14 Apr 2022 19:00:08 GMT - View all Madison, WI jobs

They will further partner with a Bioinformatics Scientist to develop and implement computational pipelines to aid data analysis and interpretation.
From University of Wisconsin–Madison - Thu, 14 Apr 2022 19:00:01 GMT - View all Madison, WI jobs

Competitive + Benefits: Arcensus: Evaluate genetic information in order to identify patients or families at risk for specific genetic disorders... Rostock, Mecklenburg-Vorpommern (DE)

Notice NOT-DA-23-004 from the NIH Guide for Grants and Contracts